DOCSLIB.ORG

ALS) with Mutations in Angiogenin and Superoxide Dismutase 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ALS) with Mutations in Angiogenin and Superoxide Dismutase 1 Therapeutic strategies for the treatment of Amyotrophic Lateral Sclerosis (ALS) with mutations in Angiogenin and Superoxide Dismutase 1 by Krishna Chaitanya Aluri Bachelor of Pharmacy, Rajiv Gandhi University of Health Sciences Master of Science in Biopharmaceutical Science, Northeastern University A dissertation submitted to The Faculty of the College of Science of Northeastern University in partial fulfillment of the requirements for the degree of Doctor of Philosophy April, 16, 2020 Dissertation directed by Jeffrey N. Agar Professor of Chemistry and Chemical Biology 1 Dedication “When I walk, I walk with you. Where I go, you're with me always.” ― Alice Hoffman, The Story Sisters, 2009. I dedicate this work to my family and friends. A special thanks to my parents Aluri Gopal Rao and Mallela Visalakshi; brother Venkata Vishnuvardan Aluri and wife Prathyusha Gundlapally for their inspiration and words of encouragement. I also dedicate this work to my friends Husain Attarwala, Arnik Shah, Aatman Doshi, Kirtika Asrani, Smith Patel and Ranjitha Gaddipati for their support. 2 Acknowledgments I would like to express my deep and sincere gratitude to Prof. Jeffrey N. Agar for continuous support and guidance. I would like to thank my fellow labmates Dr. Joseph P. Salisbury, Dr. Daniel P. Donnelly, Md. Amin Hossain, Durgalakshmi Sivasankar, and Nicholas D. Schmitt for their contributions and thoughtful discussions. I thank my thesis committee Prof. Alexander Ivanov, Prof. Ke Zhang, Dr. Jared R. Auclair, Dr. Roman Manetsch, and Dr. Saeho Chong for their insightful comments, time, and encouragement. I would like to thank our collaborators Dr. Jochen H.M. Prehn, Dr. Roman Manetsch, Dr. Adam Ekenseair, Matthew G. Dowgiallo, Brandon C. Miller, and Ninad Kanetkar for their contributions. Finally, I would like to thank my colleagues from Alnylam Pharmaceuticals for their support and encouragement throughout the process of completing my dissertation and organization Alnylam Pharmaceuticals for providing tuition assistance. 3 Abstract of Dissertation Amyotrophic Lateral Sclerosis (ALS) is a fatal progressive neurodegenerative disorder. The cause of ALS is not completely understood. About 0.5–1% of ALS cases are associated with mutations in the angiogenin (ANG). These mutations are thought to cause disease through a loss of ANG function, but this hypothesis has not been evaluated statistically. In addition, the potential for ANG to promote disease has not been considered. With the goal of better defining the etiology of ANG- ALS, we assembled all clinical onset and disease duration data and determined if these were correlated with biochemical properties of ANG variants. Loss of ANG stability and ribonuclease activity were found to correlate with early ALS onset, confirming an aspect of the prevailing model of ANG-ALS. Conversely, loss of ANG stability and ribonuclease activity correlated with longer survival following diagnosis, which is inconsistent with the prevailing model. These results indicate that functional ANG appears to decrease the risk of developing ALS but exacerbate ALS once in progress. These findings are rationalized in terms of studies demonstrating that distinct mechanisms contribute to ALS onset and progression and propose that ANG replacement or stabilization would benefit pre-symptomatic ANG-ALS patients. However, this study challenges the prevailing hypothesis that augmenting ANG will benefit symptomatic ANG-ALS patients. Instead, our results suggest that the silencing of ANG activity may be beneficial for symptomatic ALS patients. ANG has an in vivo half-life of less than 2 hours, to use ANG as prophylactic for ANG-ALS multiple doses of ANG are required daily. To mitigate this problem, we evaluated cyclic thiosulfinates as a novel class of compounds for hydrogel synthesis to encapsulate ANG. We used cyclic thiosulfinates to cross-link PEG-thiol monomers and evaluated the safety of these hydrogels 4 in vitro. Using alkylated bovine serum albumin as a surrogate to ANG (which has no free cysteines to cross-link) we demonstrated diffusion mediated sustained protein release. Finally, 2% of ALS cases were associated with mutations in superoxide dismutase 1 (SOD1). SOD1 is a homodimeric protein, in ALS-SOD1 variants the dimer destabilizes forming monomers which are prone to aggregation and are associated with toxicity. Previous studies demonstrated dimer stabilization as a viable therapeutic strategy but the cross-linkers used often form dead-end modifications with lone thiols making them harmful. Using alpha and beta lipoic acid (routinely used as dietary supplements) we demonstrated cyclic disulfides and cyclic thiosulfinates can efficiently cross-link SOD1 monomers while avoiding dead-end modifications of lone thiols. 5 Table of Contents Dedication ................................................................................................................................................... 2 Acknowledgments....................................................................................................................................... 3 Abstract of Dissertation .............................................................................................................................. 4 Table of Contents ........................................................................................................................................ 6 List of Tables .............................................................................................................................................. 9 Table of Figures ........................................................................................................................................ 10 1. Introduction ........................................................................................................................................... 12 1.1 Amyotrophic Lateral Sclerosis .................................................................................................. 12 1.2 Epidemiology in ALS ................................................................................................................ 18 1.3 Role of angiogenin in ALS ........................................................................................................ 19 1.4 Controlled protein delivery and cross-linkers for hydrogel synthesis ....................................... 20 2. Loss of angiogenin function is related to earlier ALS onset and paradoxical increase in ALS duration ................................................................................................................................................................... 22 2.1 Statement of Contribution ......................................................................................................... 23 2.2 Introduction ............................................................................................................................... 24 2.2.1 Structure and function of angiogenin ..................................................................................... 24 2.2.2 Identification of angiogenin as ALS risk factor and current hypothesis ................................ 28 2.2.3 Physicochemical properties of proteins and role in disease pathophysiology ....................... 29 2.2.4 Statistical methods.................................................................................................................. 30 6 2.3 Results ....................................................................................................................................... 38 2.3.1 Loss of ANG stability correlates with faster ALS onset ........................................................ 42 2.3.2 Loss of ANG stability and ribonuclease activity correlate with longer ALS duration .......... 45 2.3.3 Additional hypothesis testing ................................................................................................. 49 2.3.4 Preclinical validation of a possible deleterious effect of ANG post-ALS onset. ................... 59 2.4 Discussion .................................................................................................................................. 60 3. Cyclic Thiosulfinates as a Novel Class of Disulfide Cleavable Cross-linkers for Facile Hydrogel Synthesis. .................................................................................................................................................. 67 3.1 Statement of contributions ......................................................................................................... 68 3.2 Introduction ............................................................................................................................... 69 3.2.1 Hydrogels ............................................................................................................................... 69 3.2.2 Crosslinkers in Hydrogel synthesis ........................................................................................ 70 3.2.3 Cyclic Thiosulfinates.............................................................................................................. 71 3.3 Results and Discussion .............................................................................................................. 72 3.3.1 Synthesis of 1,2-dithiane-1-oxide .......................................................................................... 72 3.3.2 Cross-linking of 4-arm PEG thiol (PEG-4SH) ......................................................................
Load more

Recommended publications
  • Towards Complete Descriptions of the Free Energy Landscapes of Proteins
    Sequence-Based Predictions of Protein Solubility Michele Vendruscolo Department of Chemistry University of Cambridge Protein folding The fundamental code for protein folding is provided by the amino acid sequence. Amino acid sequences encode the whole free energy landscape of proteins Not only the native structure but also all the other states and the corresponding pathways of interconversion are encoded in the amino acid sequence of a protein. Does the amino acid sequence encode also for aggregation? Physico-chemical principles of protein aggregation Hydrophobicity, charge and secondary structure propensity are correlated with the changes in the aggregation rates upon mutation. Chiti et al. Nature 2003 Sequence-based prediction of aggregation rates The combination of sequence-dependent factors and environmental factors enables the prediction of aggregation rates over a broad range of timescales (from seconds to weeks) 0 ln(k) = åakIk + åak Ek -1 -2 ) k ( ln(k): logarithm of the aggregation rate k g o l -3 d e hydr t I : hydrophobicity a l -4 pat u c I : hydrophobic patterns l a C I : -helical propensity -5 I : -sheet propensity ch I : charge contribution -6 EpH: pH of the solution -7 -7 -6 -5 -4 -3 -2 -1 0 Eionic: ionic strength Experimental log(k ) Econc: polypeptide concentration DuBay et al. J. Mol. Biol. 2004 Prediction of aggregation-prone regions of -synuclein The aggregation propensity is a function of the physico-chemical properties of the amino acid sequence (hydrophobicity, charge, etc). We have developed the Zyggregator method to predict aggregation rates and aggregation-prone regions (www-vendruscolo.ch.cam.ac.uk) Tartaglia et al.
    [Show full text]
  • Cell Encapsulation: Promise and Progress
    COMMENTARY In cell encapsulation, transplanted cells are protected from immune rejection by an artificial, semipermeable membrane, potentially allowing transplantation (allo- or xenotransplantation) without the need for immunosuppression. Yet, despite some promising results in animal studies, the field has not lived up to expectations, and clinical products based on encapsulated cell technology continue to elude the scientific community. This commentary discusses the reasons for this, summarizes recent progress in the field and outlines what is needed to bring this technology closer to clinical application. Cell encapsulation: Promise and progress In 1964, T.M.S. Chang1 proposed the idea Some of the important considerations of using ultrathin polymer membrane GORKA ORIVE1, for consistent clinical success of cell en- microcapsules for the immunoprotection ROSA MARÍA HERNÁNDEZ1, capsulation include a source of func- of transplanted cells and introduced the ALICIA R. GASCÓN1, tional cells; a biocompatible, as well as term ‘artificial cells’ to define the concept RICCARDO CALAFIORE2, mechanically and chemically stable, of bioencapsulation, which was success- THOMAS M.S. CHANG3, membrane of a suitable permeability fully implemented 20 years later to im- PAUL DE VOS4, cut-off value that provides immune pro- mobilize xenograft islet cells. When GONZALO HORTELANO5, tection to the implant; functional per- implanted into rats, the microencapsu- DAVID HUNKELER6, IGOR LACÍK7, formance; biosafety; and long-term lated islets corrected the diabetic state for A.M. JAMES SHAPIRO8 & survival of the graft. several weeks2. Since then, there has been JOSÉ LUIS PEDRAZ1 considerable progress toward understand- Lack of clinical-grade polymers. In http://www.nature.com/naturemedicine ing the biological and technological requirements for successful the quest for a better microencapsulation design, many transplantation of encapsulated cells in experimental animal types of natural and synthetic polymers are being explored.
    [Show full text]
  • 3:15 P.M. 230. Bio-Inspired Design of a Retrievable and Scalable Cell
    Bio-inspired design of a retrievable and scalable cell encapsulation device for potential treatment of type 1 diabetes Minglin Ma Biological and Environmental Engineering, Cornell University Statement of Purpose: Cell encapsulation has been glucagon in the islets retrieved from both kidney capsule shown to hold promise for effective, long-term treatment and TRAFFIC, similar to the islets before transplantation. Human islets - kidney capsule (n=9) 500 Human islets - TRAFFIC (n=10) c Insulin Nkx6.1 of type 1 diabetes (T1D) (1-4), an unrelenting disease that a Non-diabetic control (n=4) Glucagon 450 Diabetic control (n=21) *# Nucleus 400 Transplantation Before affects millions of people. However, encapsulating 350 transplantation 300 systems developed to date still face various challenges. 250 100 µm 100 µm 200 150 Insulin Nkx6.1 For example, alginate hydrogel capsules, despite their 100 Glucagon Nucleus 0 20 40 60 80 100 120 140 160 180 Retrieved from biocompatibility and function, are difficult to retrieve or (mg/dL) glucose concentration Blood Time after STZ injections (day) Human islets - kidney capsule (n=9) Kidney capsule b Human islets - TRAFFIC (n=10) Non-diabetic control (n=4) 30 #* Diabetic control (n=21) replace in completeness due to the large number of 100 µm 100 µm 28 Transplantation 26 Insulin Nkx6.1 capsules required for effective treatment and the Glucagon 24 Nucleus complicated organ structures in the transplantation site 22 Retrieved from TRAFFIC Body weight weight (g) Body 20 18 (i.e. peritoneal space), contributing to risks and concerns 100 µm 100 µm 0 20 40 60 80 100 120 140 160 180 in case of transplant failure or medical complications.
    [Show full text]
  • Cell Encapsulation: Overcoming Barriers in Cell Transplantation in Diabetes and Beyond
    Advanced Drug Delivery Reviews 139 (2019) 92–115 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond Marco Farina a,b,1, Jenolyn F. Alexander a,1, Usha Thekkedath a, Mauro Ferrari a, Alessandro Grattoni a,⁎ a Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States b Department of Electronics and Telecommunications, Politecnico di Torino, Torino, Italy article info abstract Article history: Cell-based therapy is emerging as a promising strategy for treating a wide range of human diseases, such as di- Received 30 January 2018 abetes, blood disorders, acute liver failure, spinal cord injury, and several types of cancer. Pancreatic islets, Received in revised form 19 March 2018 blood cells, hepatocytes, and stem cells are among the many cell types currently used for this strategy. The encap- Accepted 25 April 2018 sulation of these “therapeutic” cells is under intense investigation to not only prevent immune rejection but also Available online 30 April 2018 provide a controlled and supportive environment so they can function effectively. Some of the advanced encap- Keywords: sulation systems provide active agents to the cells and enable a complete retrieval of the graft in the case of an Cell-based therapy adverse body reaction. Here, we review various encapsulation strategies developed in academic and industrial Encapsulation system settings, including the state-of-the-art technologies in advanced preclinical phases as well as those undergoing Stem cells clinical trials, and assess their advantages and challenges. We also emphasize the importance of stimulus- 3D printing responsive encapsulated cell systems that provide a “smart and live” therapeutic delivery to overcome barriers Pancreatic islets in cell transplantation as well as their use in patients.
    [Show full text]
  • Porcine Islet Encapsulation for Treatmet of Type-1 Diabetes Using Precision Particle Fabrication Method
    PORCINE ISLET ENCAPSULATION FOR TREATMET OF TYPE-1 DIABETES USING PRECISION PARTICLE FABRICATION METHOD BY BENJAMIN LEW THESIS Submitted in partial fulfillment of the requirements for the degree of Master of Science in Bioengineering in the Graduate College of the University of Illinois at Urbana-Champaign, 2016 Urbana, Illinois Advisers: Professor Kyekyoon (Kevin) Kim Research Professor Hyungsoo Choi ABSTRACT Type-1 diabetes (T1D), also known as insulin-dependent diabetes, is characterized by the inability of pancreas to produce sufficient amount of insulin to regulate blood glucose level in the body. Long-term complications such as nephropathy, neuropathy, retinopathy and cardiovascular disease make T1D a major health problem throughout the world. For the past few decades, allotransplantation of insulin-producing islets from the pancreas of deceased human donors has shown promising results in the restoration and sustenance of normoglycemia. Islet transplantation is a suitable procedure, especially for adolescents since it has substantially lower risk in operating procedure than whole-pancreas transplantation. However, only small percentage of patients of T1D can be treated with islet allotransplantation because of the limited donor availability. Xenotransplantation using porcine islet is a good alternative treatment of T1D. Porcine islet is an ideal substitute of beta cell function for human islet for several reasons: availability, compatibility and functional similarity to human islets. In recent years, treatment with porcine islets has shown significant progress of providing sustained normoglycemia in diabetes-induced nonhuman primates (NHPs), which has demonstrated the feasibility of clinical xenotransplantation. Yet, there are still a number of barriers to overcome in order to accomplish successful clinical application for xenotransplantation.
    [Show full text]
  • Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
    Immun., Endoc. & Metab. Agents in Med. Chem., 2006, 6, 139-153 139 Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes Paul de Vos1,*, A. Andersson2, S.K. Tam3, M.M. Faas1 and J.P. Hallé3 1Department of Pathology and Laboratory Medicine, University Hospital of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands; 2Department of Medical Cell Biology, University of Uppsala, PO Box 571, SE-75123 Uppsala, Sweden and 3Centre de recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, Québec, Canada, H1T 2M4 Abstract: Mammalian cell encapsulation is under investigation for the treatment of a wide variety of diseases, since it allows for transplantation of endocrine cells in the absence of undesired immunosuppression. The technology is based on the principle that transplanted tissue is protected for the host immune system by an artificial membrane. In spite of the simplicity of the concept, progress in the field of immuno-isolation has been hampered. During the past two decades, three major approaches of encapsulation have been studied. These include (i) intravascular macrocapsules, which are anastomosed to the vascular system as AV shunt, (ii) extravascular macrocapsules, which are mostly diffusion chambers transplanted at different sites, and (iii) extravascular microcapsules transplanted in the peritoneal cavity. The advantages and pitfalls of the three approaches are discussed and compared in view of applicability in clinical islet transplantation. At present, microcapsules, due to their spatial characteristics, offer better diffusion capacity than mac- rocapsules. During the past five years, important advances have been made in the knowledge of the characteristics and requirements capsules have to meet in order to provide optimal biocompatibility and survival of the enveloped tissue.
    [Show full text]
  • Islet Encapsulation: Physiological Possibilities and Limitations
    1748 Diabetes Volume 66, July 2017 Islet Encapsulation: Physiological Possibilities and Limitations Olle Korsgren Diabetes 2017;66:1748–1754 | https://doi.org/10.2337/db17-0065 A logical cure for type 1 diabetes (T1D) involves replacing insulin-producing cells will be available for clinical testing. the lost insulin-producing cells with new ones, preferably The particular problems of generating glucose-responsive cells from a well-characterized and unlimited source of insulin-producing cells were recently elegantly reviewed human insulin-producing cells. This straightforward and and will not further be discussed in this Perspective (3). simple solution to provide a cure for T1D is immensely The current indications for clinical islet transplantation attractive but entails at least two inherent and thus far are 1) severe unawareness of hypoglycemia and 2) trans- 1 unresolved hurdles: ) provision of an unlimited source of plantation to subjects already on systemic immunosuppres- 2 functional human insulin-producing cells and )preven- sion, most often because of a previous or simultaneous tion of rejection without the side effects of systemic kidney transplant. At present, there is no major shortage immunosuppression. Generation of transplantable insulin- of primary human islets, i.e., those obtained from organ producing cells from human embryonic stem cells or in- donors, to fulfill the current indications for clinical islet duced pluripotent stem cells is at present close to reality, transplantation; a shortage of insulin-producing cells will and we are currently awaiting the first clinical studies. Focus is now directed to foster development of novel only occur if we can control immune-mediated rejection means to control the immune system to enable large- of the transplanted cells without the need for systemic scale clinical application.
    [Show full text]
  • Embryonic Stem Cells As a Cell Source for Tissue Engineering
    CHAPTER 32 Embryonic Stem Cells as a Cell Source for Tissue Engineering Ali Khademhosseini1,2, Jeffrey M. Karp1,2, Sharon Gerecht-Nir3, Lino Ferreira3, Nasim Annabi1,2, Dario Sirabella4, Gordana Vunjak-Novakovic4 and Robert Langer1,3 1 Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 2 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 3 Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 4 Department of Biomedical Engineering and Department of Medicine, Columbia University, New York, New York 609 INTRODUCTION It has been estimated that approximately 3,000 people die every day in the US from dis- eases that could have been treated with stem cell-derived tissues [1]. Given the therapeutic potential and growing public awareness of stem cells to treat disease, it is not surprising that embryonic stem cell (ESC) research has been rapidly expanding since mouse ESCs (mESCs) were first isolated in 1981 [2,3] followed by the isolation of human embryonic stem cells (hESCs) in 1998 [4,5] from the inner cell mass (ICM) of human blastocysts (Fig. 32.1). Adult stem cells have been used clinically since the 1960s for therapies such as bone marrow transplantation, and these cells hold great therapeutic promise. ESCs also offer major benefits, including their ease of isolation, ability to propagate rapidly without differentiation, and e most significantly e their potential to form all cell types in the body. Additionally, ESCs are an attractive cell source for the study of developmental biology, drug/toxin screening studies, and the development of therapeutic agents to aid in tissue or organ replacement therapies.
    [Show full text]
  • Cabimer 2011-15
    2 INDEX 5 Welcome/Introduction by the Director 7 Cabimer by the Manager 9 Description of Research Activities 10 Molecular Biology Department Genome Instability & Cáncer Epigenetics and Gene Expression Chromatin Integrity and Function Mitochondrial Plasticity and Replication Chromosome Segregation 20 Stem Cell Department Cellular Therapy of the Diabetes Mellitus and its Complication Pancreatic Islets Pathophysiology Cell and Stem Cell Pancreas and Liver Development and Disease Pancreatic Isled Development and Regeneration Unit Cell Differentiation Laboratory DNA Damage Response 32 Cell Signalling Department Cell Death Signalling Cell Cicle and Oncogenesis Membrabe Traffic and Cytoskeleton in Cell Dynamics Neuronal Plasticity and Neurodegenerative Diseases Advance Therapy in Neuroprotection and Immune Regulation 42 Cell Therapy and Regenerative Medicine Department Retinal Degeneration: from Genetics to Therapy Survival Mechanisms of the Pancreatic Islets Cell Therapy for Neuropathologies DNA Double Strand Breaks Repair and Human Disease 51 Scientific Core Services Biological Safety Unit Biological Resources Cell Culture Citometry and Sorter GMP Genomics Microscopy Histology Model Organism Washing and Sterilization 61 General Core Services 62 Communication and Diffusion Publications Doctoral Theses Seminar Speakers 79 Master Students 81 Scientific Advisory Board 83 Where we are 3 4 WELCOME Andres Aguilera [email protected] DIRECTOR It is my pleasure to present the scientific report of CABIMER (Centro EMBO Young Investigators (Felipe Cortés and Pablo Huertas), or the Andaluz de Biología Molecular y Medicina Regenerativa / Andalusian recognition of several researchers of highly valuable research prizes Centre of Molecular Biology and Regenerative Medicine) for the pe- and distinctions (Benoit Gauthier, Felipe Cortés-Ledesma, Andrés riod 2011 to 2015. CABIMER is a groundbreaking multidisciplinary Aguilera).
    [Show full text]
  • Cell Encapsulation Could Enhance Antiviral Vaccines
    Rue Gabrielle-Perret-Gentil 4 CH – 1211 Genève 14 Press Release Geneva, 27 May 2021 CELL ENCAPSULATION COULD ENHANCE ANTIVIRAL VACCINES Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called "cell encapsulation". Originally designed to stimulate immunity to fight cancer, the COVID-19 pandemic motivated the scientists to broaden the scope of their technology to test its effectiveness against viruses. The first results of a pre-clinical study are very encouraging and can be discovered in the journal Vaccines. The immune system is able to identify cancer cells and fight them, just as it does against a viral or bacterial pathogen. Researchers therefore rely on this to develop vaccines against cancer. "To develop an effective vaccine, two elements are needed: a target recognized by the immune system, such as cells, proteins, DNA or RNA sequences, and an adjuvant able to effectively stimulate the immune response", says Nicolas Mach, an oncologist at the HUG Division of Oncology, and a professor at UNIGE Faculty of Medicine Department of Medicine and Translational Research Centre in Onco-Haematology, and co-author of this study. To this end, Nicolas Mach and his team, in partnership with the company MaxiVAX, developed a novel cell-based cancer vaccination using cell encapsulation technology. With the coronavirus pandemic and the need to develop effective vaccines, they decided to extend the scope of this technology to test its effectiveness against viruses.
    [Show full text]
  • A Natural Product Inhibits the Initiation of Α-Synuclein Aggregation And
    Correction NEUROSCIENCE Correction for “A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity,” by Michele Perni, Céline Galvagnion, Alexander Maltsev, Georg Meisl, Martin B. D. Müller, Pavan K. Challa, Julius B. Kirkegaard, Patrick Flagmeier, Samuel I. A. Cohen, Roberta Cascella, Serene W. Chen, Ryan Limboker, Pietro Sormanni, Gabriella T. Heller, Francesco A. Aprile, Nunilo Cremades, Cristina Cecchi, Fabrizio Chiti, Ellen A. A. Nollen, Tuomas P. J. Knowles, Michele Vendruscolo, Adriaan Bax, Michael Zasloff, and Christopher M. Dobson, which appeared in issue 6, February 7, 2017, of Proc Natl Acad Sci USA (114:E1009– E1017; first published January 17, 2017; 10.1073/pnas.1610586114). The authors note that Ryan Limbocker’s name incorrectly appeared as Ryan Limboker. The corrected author line appears below. The online version has been corrected. Michele Perni, Céline Galvagnion, Alexander Maltsev, Georg Meisl, Martin B. D. Müller, Pavan K. Challa, Julius B. Kirkegaard, Patrick Flagmeier, Samuel I. A. Cohen, Roberta Cascella, Serene W. Chen, Ryan Limbocker, Pietro Sormanni, Gabriella T. Heller, Francesco A. Aprile, Nunilo Cremades, Cristina Cecchi, Fabrizio Chiti, Ellen A. A. Nollen, Tuomas P. J. Knowles, Michele Vendruscolo, Adriaan Bax, Michael Zasloff, and Christopher M. Dobson www.pnas.org/cgi/doi/10.1073/pnas.1701964114 CORRECTION www.pnas.org PNAS | March 21, 2017 | vol. 114 | no. 12 | E2543 Downloaded by guest on September 28, 2021 A natural product inhibits the initiation of α-synuclein PNAS PLUS aggregation and suppresses its toxicity Michele Pernia,b, Céline Galvagniona,1, Alexander Maltsevc, Georg Meisla, Martin B. D. Müllera,b, Pavan K. Challaa, Julius B.
    [Show full text]
  • By Yulong Sun a Thesis Submitted in Conform
    MOLECULAR MECHANISMS OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA: NEW INSIGHTS INTO THE FORMATION OF TDP-43 PROTEIN ASSEMBLIES by Yulong Sun A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Medical Biophysics University of Toronto © Copyright by Yulong Sun 2018 Molecular Mechanisms of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: New Insights into the Formation of TDP-43 Protein Assemblies Yulong Sun Doctor of Philosophy Department of Medical Biophysics University of Toronto 2018 Abstract Advances in modern medicine in the past century have dramatically improved the average life expectancy in the western world. Unfortunately, the molecular mechanisms that maintain the integrity of proteins in the body appear to be unable to keep pace. This has led to a growing prevalence of late-onset diseases involving abnormal accumulation of proteins, especially in the last century. The increase in occurrence of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and transmissible spongiform encephalopathies such as prion disease, has become a great burden to the healthcare system. All of these diseases are currently incurable and fatal, but they share the common hallmark of misfolding and aggregation of proteins within the effected neurons. The discovery and characterization of such proteins have often led to the identification of potential targets for treatment and drug design. In the case of ALS, progressive death of upper and lower motor neurons leads to full-body paralysis, and patient death from respiratory failure. The cause of ALS is currently unknown, but remarkably, regardless of the type of ALS (familial or sporadic), the RNA binding protein, TDP-43, is found in 97% of cases as neuronal inclusions, suggesting a mechanistic role in disease pathogenesis.
    [Show full text]